COVID-19 associated seizures may increase death risk in patients

COVID-19 can have damaging effects on multiple organs in the body, including the brain. A new study led by investigators at Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center (BIDMC) indicates that some hospitalized patients with COVID-19 experience non-convulsive seizures, which may put them at a higher risk of dying. The findings are published in the Annals of Neurology.

Seizures are a very common complication of severe critical illness. Most of these seizures are not obvious: Unlike seizures that make a person fall down and shake, or convulse, seizures in critically ill patients are usually nonconvulsive. There is increasing evidence that non-convulsive seizures can damage the brain and make outcomes worse, similar to convulsions."

M. Brandon Westover, MD, PhD, Study Co-Senior Author and Investigator, Department of Neurology at MGH and Director of Data Science at the MGH McCance Center for Brain Health, Massachusetts General Hospital

Westover notes that there have been only a few small reports of seizures in patients with severe COVID-19 illness, and it was previously unclear whether such seizures primarily occur in patients who already have a seizure disorder or whether they can arise for the first time because of COVID-19. The effects of such seizures on patients' health were also unknown.

To provide insights, Westover and his colleagues analyzed medical information for 197 hospitalized patients with COVID-19 who underwent electroencephalogram (EEG) monitoring--tests that detect electrical activity of the brain using small metal discs attached to the scalp--for various reasons at nine institutions in North America and Europe.

The EEG tests detected nonconvulsive seizures in 9.6% of patients, some of whom had no prior neurological problems. Patients who had seizures needed to be hospitalized for a longer time, and they were four times more likely to die while in the hospital than patients without seizures--suggesting that neurological complications may be an important contributor to the morbidity and mortality associated with COVID-19.

"We found that seizures indeed can happen in patients with COVID-19 critical illness, even those without any prior neurologic history and that they are associated with worse outcomes: higher rates of death and longer hospital stay, even after adjusting for other factors," says co-senior author Mouhsin Shafi, MD, Ph.D., an investigator in the Department of Neurology at BIDMC, medical director of the BIDMC EEG laboratory, and director of the Berenson-Allen Center for Noninvasive Brain Stimulation.

"Our results suggest that patients with COVID-19 should be monitored closely for nonconvulsive seizures. Treatments are available and warranted in patients at high risk; however, further research is needed to clarify how aggressively to treat seizures in COVID-19."

Westover is an associate professor of Neurology at Harvard Medical School (HMS) and Shafi is an assistant professor of Neurology at HMS.

Sources:
Journal reference:

Lin, L., et al. (2021) Electroencephalographic Abnormalities are Common in COVID‐19 and are Associated with Outcomes. Annals of Neurology. doi.org/10.1002/ana.26060.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients